Literature DB >> 25198449

Expired and Pathogen-Inactivated Platelet Concentrates Support Differentiation and Immunomodulation of Mesenchymal Stromal Cells in Culture.

Sandra Mjoll Jonsdottir-Buch1, Hildur Sigurgrimsdottir, Ramona Lieder, Olafur Eysteinn Sigurjonsson.   

Abstract

Platelet lysates have been reported as suitable cell culture supplement for cultures of mesenchymal stromal cells (MSCs). The demand for safe and animal-free cultures of MSCs is linked to the potential application of MSCs in clinics. While the use of platelet lysates offers an alternative to animal serum in MSC cultures, obtaining supplies of fresh platelet concentrates for lysate production is challenging and raises concerns due to the already existing shortage of platelet donors. We have previously demonstrated that expired platelet concentrates may represent a good source of platelets for lysate production without competing with blood banks for platelet donors. The INTERCEPT Blood System™ treatment of platelet concentrates allows for prolonged storage up to 7 days, using highly specific technology based on amotosalen and UV-A light. The INTERCEPT system has therefore been implemented in blood processing facilities worldwide. In this study, we evaluated the suitability of INTERCEPT-treated, expired platelet concentrates, processed into platelet lysates, for the culture of MSCs compared to nontreated expired platelets. Bone marrow-derived MSCs were cultured in media supplemented with either platelet lysates from traditionally prepared expired platelet concentrates or in platelet lysates from expired and pathogen-inactivated platelet concentrates. The effects of pathogen inactivation on the ability of the platelets to support MSCs in culture were determined by evaluating MSC immunomodulation, immunophenotype, proliferation, and trilineage differentiation. Platelet lysates prepared from expired and pathogen-inactivated platelet concentrates supported MSC differentiation and immunosuppression better compared to traditionally prepared platelet lysates from expired platelet units. Pathogen inactivation of platelets with the INTERCEPT system prior to use in MSC culture had no negative effects on MSC immunophenotype or proliferation. In conclusion, the use of expired pathogen-inactivated platelet units from blood banks to prepare platelet lysates for the culture of MSCs is desirable and attainable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25198449     DOI: 10.3727/096368914X683043

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  8 in total

Review 1.  [Mesenchymal stem/stroma cells : Therapeutic potential in the treatment of autoimmune diseases].

Authors:  R Schäfer; T Daikeler
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

2.  Comparative analyses of industrial-scale human platelet lysate preparations.

Authors:  Jan Pierce; Eric Benedetti; Amber Preslar; Pam Jacobson; Ping Jin; David F Stroncek; Jo-Anna Reems
Journal:  Transfusion       Date:  2017-10-08       Impact factor: 3.157

Review 3.  Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future.

Authors:  Giuseppe Astori; Eliana Amati; Franco Bambi; Martina Bernardi; Katia Chieregato; Richard Schäfer; Sabrina Sella; Francesco Rodeghiero
Journal:  Stem Cell Res Ther       Date:  2016-07-13       Impact factor: 6.832

Review 4.  Can the administration of platelet lysates to the brain help treat neurological disorders?

Authors:  Ouada Nebie; Luc Buée; David Blum; Thierry Burnouf
Journal:  Cell Mol Life Sci       Date:  2022-06-24       Impact factor: 9.207

5.  Pathogen reduction through additive-free short-wave UV light irradiation retains the optimal efficacy of human platelet lysate for the expansion of human bone marrow mesenchymal stem cells.

Authors:  Sabrina Viau; Lucie Chabrand; Sandy Eap; Judith Lorant; Karl Rouger; Francis Goudaliez; Chryslain Sumian; Bruno Delorme
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

6.  Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study.

Authors:  Christian Christensen; Sandra Mjoll Jonsdottir-Buch; Olafur Eysteinn Sigurjonsson
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

7.  The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates.

Authors:  Ouada Nebie; David Devos; Valérie Vingtdeux; Lassina Barro; Jean-Christophe Devedjian; Aurélie Jonneaux; Ming-Li Chou; Régis Bordet; Luc Buée; Folke Knutson; David Blum; Thierry Burnouf
Journal:  J Biomed Sci       Date:  2019-10-31       Impact factor: 8.410

Review 8.  Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production.

Authors:  Michaela Oeller; Sandra Laner-Plamberger; Linda Krisch; Eva Rohde; Dirk Strunk; Katharina Schallmoser
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.